The case for assessing the full value of new tuberculosis vaccines
Eur Respir J
.
2020 Mar 20;55(3):1902414.
doi: 10.1183/13993003.02414-2019.
Print 2020 Mar.
Authors
Nebiat Gebreselassie
1
,
Raymond Hutubessy
2
,
Johan Vekemans
2
,
Saskia den Boon
2
,
Tereza Kasaeva
3
,
Matteo Zignol
3
Affiliations
1
Global TB Programme, World Health Organization, Geneva, Switzerland
[email protected]
.
2
Dept of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
3
Global TB Programme, World Health Organization, Geneva, Switzerland.
PMID:
32198269
DOI:
10.1183/13993003.02414-2019
No abstract available
Publication types
Editorial
MeSH terms
BCG Vaccine
Humans
Mycobacterium tuberculosis*
Tuberculosis Vaccines*
Tuberculosis* / diagnosis
Tuberculosis* / prevention & control
Substances
BCG Vaccine
Tuberculosis Vaccines
Grants and funding
001/WHO_/World Health Organization/International